Cidara Therapeutics Inc (NASDAQ:CDTX)‘s stock had its “buy” rating reiterated by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Friday. They currently have a $20.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 73.16% from the stock’s previous close.

The analysts wrote, “Analysts Offer Insights on Healthcare Companies: Cidara Therapeutics (NASDAQ: CDTX) and Corvus Pharmaceuticals Inc (NASDAQ: CRVS) | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=99b8148e24&wpp_id=459972’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Analysts Offer Insights on Healthcare Companies: Cidara Therapeutics (NASDAQ: CDTX) and Corvus Pharmaceuticals Inc (NASDAQ: CRVS)”

A number of other research firms have also weighed in on CDTX. Zacks Investment Research lowered shares of Cidara Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 15th. Wedbush reiterated an “outperform” rating on shares of Cidara Therapeutics in a research report on Tuesday, August 16th. Needham & Company LLC reiterated a “buy” rating and issued a $20.00 price target on shares of Cidara Therapeutics in a research report on Monday, August 15th. BTIG Research reiterated a “buy” rating and issued a $24.00 price target on shares of Cidara Therapeutics in a research report on Monday, August 15th. Finally, WBB Securities lowered shares of Cidara Therapeutics from a “hold” rating to a “sell” rating and set a $10.50 price target for the company. in a research report on Friday, September 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $18.25.

Analyst Recommendations for Cidara Therapeutics (NASDAQ:CDTX)

Cidara Therapeutics (NASDAQ:CDTX) opened at 11.55 on Friday. Cidara Therapeutics has a 12-month low of $8.65 and a 12-month high of $18.07. The company’s market cap is $192.57 million. The company’s 50 day moving average is $10.27 and its 200 day moving average is $11.15.

Several institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its position in Cidara Therapeutics by 65.0% in the second quarter. Bank of New York Mellon Corp now owns 27,075 shares of the biotechnology company’s stock valued at $279,000 after buying an additional 10,661 shares during the period. California State Teachers Retirement System increased its stake in Cidara Therapeutics by 119.1% in the second quarter. California State Teachers Retirement System now owns 22,491 shares of the biotechnology company’s stock worth $232,000 after buying an additional 12,225 shares during the last quarter. Emerald Acquisition Ltd. acquired a new stake in Cidara Therapeutics during the second quarter worth about $183,000. Turner Investments L.P. acquired a new stake in Cidara Therapeutics during the second quarter worth about $283,000. Finally, Nationwide Fund Advisors increased its stake in Cidara Therapeutics by 20.7% in the second quarter. Nationwide Fund Advisors now owns 20,609 shares of the biotechnology company’s stock worth $212,000 after buying an additional 3,539 shares during the last quarter. 49.97% of the stock is currently owned by hedge funds and other institutional investors.

About Cidara Therapeutics

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

5 Day Chart for NASDAQ:CDTX

Receive News & Stock Ratings for Cidara Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc and related stocks with our FREE daily email newsletter.